3C-P, also known as 4-propoxy-3,5-dimethoxyamphetamine or as ñ-methylproscaline (3C-proscaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine (TMA). It is the amphetamine (3C) analogue of proscaline.
3C-P has been reported to have a dose range of 20 to 40mg orally, with a typical dose estimate of 30mg, based on informal anecdotal reports. Although 3C-P produces hallucinogenic effects, very little is known about its effects.
3C-P acts as a serotonin 5-HT<sub>2</sub> receptor agonist, including of the serotonin 5-HT<sub>2A</sub> receptor. It produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.
The chemical synthesis of 3C-P has been described.
Analogues of 3C-P include TMA, MEM, 3C-E, 3C-AL, 3C-MAL, and 3C-FP, among others.
3C-P was first described in the scientific literature by Otakar Leminger by 1972. Alexander Shulgin mentioned it in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved) and Daniel Trachsel synthesized it in 2002, but neither of them reported its properties or effects in humans. The drug has been sold online as a designer drug and was first detected in September 2013 in Finland.
3C-P is a controlled substance in Canada under amphetamine blanket-ban language.
3C-P is not an explicitly controlled substance in the United States, although it would most likely be considered a controlled substance under the Federal Analogue Act as an analogue of 2C-P.